Samsung BioLogics Eyes Global Leadership Via Korean IPO
This article was originally published in PharmAsia News
Executive Summary
In its ongoing efforts to become the world's top biopharmaceutical manufacturing company, Samsung BioLogics has decided to launch an initial public offering in the benchmark Korean stock market this year amid weak biotech sentiment in the US. Proceeds from the IPO, poised to be one of the biggest domestic IPOs, will be used for further expansion of its manufacturing facilities.
You may also be interested in...
Samsung BioLogics IPO May Set Tone For Korean Biopharma Investors
Samsung BioLogics has set out plans for one of the biggest ever IPOs in South Korea that could help reignite investor sentiment battered by recent events surrounding Hanmi.
What Would It Take To Attract Global Pharmas To Korea?
What do successful biopharma countries have in common? At a recent biopharma industry seminar in Incheon, South Korea, delegates stressed the importance of creating strong bioclusters if the country is to transform itself into a biopharma-focused nation.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.